REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis
Christopher Ma(University of Calgary), Talat Bessissow(Montreal General Hospital), Catherine Tsai(University of Alberta), Marica Reise-Filteau(University of British Columbia), Yasi Xiao(University of Toronto), Vipul Jairath(McMaster University), Yuvan Khandelwal(University of Ottawa), Neeraj Narula(McMaster University), Sanjay K. Murthy(University of Ottawa), Rocío Sedaño, Brian Bressler(University of British Columbia), Farhad Peerani(University of Alberta), Dustin Loomes(Island Health), Emily C L Wong(Population Health Research Institute), Samantha Y. Starkey(University of British Columbia), Remo Panaccione(University of Calgary)
Cited by 45
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k